Sökning: WFRF:(Hamadani M) >
Reduced-Intensity A...
-
Klyuchnikov, EvgenyUniv Canc Ctr Hamburg, Dept Stem Cell Transplantat, Hamburg, Germany.
(författare)
Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors
- Artikel/kapitelEngelska2015
Förlag, utgivningsår, omfång ...
-
Elsevier BV,2015
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-270421
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-270421URI
-
https://doi.org/10.1016/j.bbmt.2015.07.028DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:132455562URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
This study was conducted to compare long-term outcomes in patients with refractory/relapsed grades 1 and 2 follicular lymphoma (FL) after allogeneic (allo) versus autologous (auto) hematopoietic cell transplantation (HCT) in the rituximab era. Adult patients with relapsed/refractory grades 1 and 2 FL undergoing first reduced-intensity allo-HCT or first autograft during 2000 to 2012 were evaluated. A total of 518 rituximab-treated patients were included. Allo-HCT patients were younger and more heavily pretreated, and more patients had advanced stage and chemoresistant disease. The 5-year adjusted probabilities, comparing auto-HCT versus allo-HCT groups for nonrelapse mortality (NRM) were 5% versus 26% (P <.0001); relapse/progression: 54% versus 20% (P <.0001); progression-free survival (PFS): 41% versus 58% (P <.001), and overall survival (OS): 74% versus 66% (P =.05). Auto-HCT was associated with a higher risk of relapse/progression beyond 5 months after HCT (relative risk [RR], 4.4; P <.0001) and worse PFS (RR, 2.9; P <.0001) beyond 11 months after HCT. In the first 24 months after HO', auto-HCT was associated with improved OS (RR,.41; P <.0001), but beyond 24 months, it was associated with inferior OS (RR, 2.2; P =.006). A landmark analysis of patients alive and progression-free at 2 years after HO' confirmed these observations, showing no difference in further NRM between both groups, but there was significantly higher risk of relapse/progression (RR, 7.3; P <.0001) and inferior PFS (RR, 3.2; P <.0001) and OS (RR, 2.1; P =.04) after auto-HCT. The 10-year cumulative incidences of second hematological malignancies after allo-HCT and auto-HCT were 0% and 7%, respectively. Auto-HCT and reduced-intensity conditioned allo-HCT as first transplantation approach can provide durable disease control in grades 1 and 2 FL patients. Continued disease relapse risk after auto-HCT translates into improved PFS and OS after allo-HCT in long-term survivors.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Bacher, UlrikeUniv Gottingen, Dept Hematol & Internal Oncol, D-37073 Gottingen, Germany.
(författare)
-
Kroeger, Nicolaus M.Univ Canc Ctr Hamburg, Dept Stem Cell Transplantat, Hamburg, Germany.
(författare)
-
Hari, Parameswaran N.Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.
(författare)
-
Ahn, Kwang WooMed Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA.
(författare)
-
Carreras, JeanetteMed Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.
(författare)
-
Bachanova, VeronikaUniv Minnesota, Med Ctr, Bone & Marrow Transplant Program, Minneapolis, MN 55455 USA.
(författare)
-
Bashey, AsadNorthside Hosp, Blood & Marrow Transplant Program, Atlanta, GA USA.
(författare)
-
Cohen, Jonathon B.Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA.
(författare)
-
D'Souza, AnitaMed Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.
(författare)
-
Freytes, Cesar O.South Texas Vet Hlth Care Syst, San Antonio, TX USA.;Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.;Univ London Imperial Coll Sci Technol & Med, Dept Med, Div Expt Med, Hematol Res Ctr, London, England.
(författare)
-
Gale, Robert Peter
(författare)
-
Ganguly, SiddharthaUniv Kansas, Med Ctr, Blood & Marrow Transplantat, Div Hematol & Oncol, Kansas City, KS 66103 USA.
(författare)
-
Hertzberg, Mark S.Prince Wales Hosp, Dept Haematol, Randwick, NSW 2031, Australia.
(författare)
-
Holmberg, Leona A.Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
(författare)
-
Kharfan-Dabaja, Mohamed A.H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA.
(författare)
-
Klein, AndreasTufts Med Ctr, Div Hematol Oncol, Dept Med, Boston, MA USA.
(författare)
-
Ku, Grace H.Univ Calif San Diego, Dept Med, Div Blood & Marrow Transplantat, San Diego, CA 92103 USA.
(författare)
-
Laport, Ginna G.Stanford Hosp & Clin, Div Bone Marrow Transplantat, Stanford, CA USA.
(författare)
-
Lazarus, Hillard M.Univ Hosp Case Med Ctr, Seidman Canc Ctr, Cleveland, OH USA.
(författare)
-
Miller, Alan M.Baylor Univ, Med Ctr, Dept Oncol, Dallas, TX USA.
(författare)
-
Mussetti, AlbertoFdn IRCCS Ist Nazl Tumori, SC Ematol & Trapianto Midollo Osseo, Milan, Italy.;Univ Milan, Milan, Italy.
(författare)
-
Olsson, Richard F.Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Div Therapeut Immunol, Dept Lab Med, Stockholm, Sweden.(Swepub:uu)riols677
(författare)
-
Slavin, ShimonInt Ctr Cell Therapy & Canc Immunotherapy, Tel Aviv, Israel.
(författare)
-
Usmani, Saad Z.Carolinas HealthCare Syst, Levine Canc Inst, Dept Hematol, Med Oncol, Charlotte, NC USA.
(författare)
-
Vij, RaviWashington Univ, Sch Med, Div Hematol & Oncol, St Louis, MO USA.
(författare)
-
Wood, William A.Univ N Carolina, Dept Med, Div Hematol Oncol, Chapel Hill, NC USA.
(författare)
-
Maloney, David G.Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
(författare)
-
Sureda, Anna M.Hosp Duran & Reynals, Inst Catala Oncol, Serv Hematol, Barcelona, Spain.;European Grp Blood & Marrow Transplantat, Milan, Italy.
(författare)
-
Smith, Sonali M.Univ Chicago, Sect Hematol Oncol, Chicago, IL 60637 USA.
(författare)
-
Hamadani, MehdiMed Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.
(författare)
-
Univ Canc Ctr Hamburg, Dept Stem Cell Transplantat, Hamburg, Germany.Univ Gottingen, Dept Hematol & Internal Oncol, D-37073 Gottingen, Germany.
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Biology of blood and marrow transplantation: Elsevier BV21:12, s. 2091-20991083-87911523-6536
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Klyuchnikov, Evg ...
-
Bacher, Ulrike
-
Kroeger, Nicolau ...
-
Hari, Parameswar ...
-
Ahn, Kwang Woo
-
Carreras, Jeanet ...
-
visa fler...
-
Bachanova, Veron ...
-
Bashey, Asad
-
Cohen, Jonathon ...
-
D'Souza, Anita
-
Freytes, Cesar O ...
-
Gale, Robert Pet ...
-
Ganguly, Siddhar ...
-
Hertzberg, Mark ...
-
Holmberg, Leona ...
-
Kharfan-Dabaja, ...
-
Klein, Andreas
-
Ku, Grace H.
-
Laport, Ginna G.
-
Lazarus, Hillard ...
-
Miller, Alan M.
-
Mussetti, Albert ...
-
Olsson, Richard ...
-
Slavin, Shimon
-
Usmani, Saad Z.
-
Vij, Ravi
-
Wood, William A.
-
Maloney, David G ...
-
Sureda, Anna M.
-
Smith, Sonali M.
-
Hamadani, Mehdi
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
- Artiklar i publikationen
-
Biology of blood ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet